CA2991634A1 - Multivalent and multispecific dr5-binding fusion proteins - Google Patents

Multivalent and multispecific dr5-binding fusion proteins Download PDF

Info

Publication number
CA2991634A1
CA2991634A1 CA2991634A CA2991634A CA2991634A1 CA 2991634 A1 CA2991634 A1 CA 2991634A1 CA 2991634 A CA2991634 A CA 2991634A CA 2991634 A CA2991634 A CA 2991634A CA 2991634 A1 CA2991634 A1 CA 2991634A1
Authority
CA
Canada
Prior art keywords
seq
isolated polypeptide
amino acid
acid sequence
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2991634A
Other languages
English (en)
French (fr)
Inventor
John C. Timmer
Kyle S. JONES
Amir S. RAZAI
Abrahim HUSSAIN
Katelyn M. WILLIS
Quinn Deveraux
Brendan P. Eckelman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inhibrx Inc
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Publication of CA2991634A1 publication Critical patent/CA2991634A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001138—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2991634A 2015-07-16 2016-07-18 Multivalent and multispecific dr5-binding fusion proteins Pending CA2991634A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562193309P 2015-07-16 2015-07-16
US62/193,309 2015-07-16
PCT/US2016/042862 WO2017011837A2 (en) 2015-07-16 2016-07-18 Multivalent and multispecific dr5-binding fusion proteins

Publications (1)

Publication Number Publication Date
CA2991634A1 true CA2991634A1 (en) 2017-01-19

Family

ID=57757772

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2991634A Pending CA2991634A1 (en) 2015-07-16 2016-07-18 Multivalent and multispecific dr5-binding fusion proteins

Country Status (25)

Country Link
US (4) US10308720B2 (OSRAM)
EP (2) EP3322734B1 (OSRAM)
JP (4) JP6807606B2 (OSRAM)
KR (2) KR20250017305A (OSRAM)
CN (2) CN107922491B (OSRAM)
AU (2) AU2016291701B2 (OSRAM)
CA (1) CA2991634A1 (OSRAM)
CY (1) CY1123615T1 (OSRAM)
DK (1) DK3322734T3 (OSRAM)
ES (1) ES2833773T3 (OSRAM)
HR (1) HRP20201785T1 (OSRAM)
HU (1) HUE051896T2 (OSRAM)
IL (3) IL307994A (OSRAM)
LT (1) LT3322734T (OSRAM)
MX (2) MX2018000523A (OSRAM)
NZ (1) NZ777930A (OSRAM)
PL (1) PL3322734T3 (OSRAM)
PT (1) PT3322734T (OSRAM)
RS (1) RS61062B1 (OSRAM)
RU (2) RU2748620C2 (OSRAM)
SG (1) SG10201912410TA (OSRAM)
SI (1) SI3322734T1 (OSRAM)
SM (1) SMT202100066T1 (OSRAM)
WO (1) WO2017011837A2 (OSRAM)
ZA (1) ZA201800238B (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL269826B1 (en) 2017-04-11 2025-09-01 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
WO2019129644A1 (en) * 2017-12-28 2019-07-04 Julius-Maximilians-Universität Würzburg TUMOR NECROSIS FACTOR (TNF) RECEPTOR SUPERFAMILY (TNFRSF) RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FcγR-INDEPENDENT AGONISTIC ACTIVITY (TNFRSF RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCγR-INDEPENDENT AGONISTIC ACTIVITY; TRAAFFIAA)
CN110305210B (zh) * 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
JP7724061B2 (ja) 2018-04-11 2025-08-15 インヒブルクス バイオサイエンシズ インコーポレイテッド 制約されたｃｄ３結合を有する多重特異性ポリペプチド構築物ならびに関連する方法および使用
WO2020047705A1 (zh) * 2018-09-03 2020-03-12 安菲尼生命科技有限公司 Dr5单域抗体及其用途
GB201903767D0 (en) * 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
EP4041398A1 (en) * 2019-10-01 2022-08-17 Epsilogen Ltd Hybrid antibody
EP4154910A4 (en) * 2020-06-30 2024-09-11 Harbour Biomed (Shanghai) Co., Ltd Binding protein having h2l2 and hcab structures
EP4294842A1 (en) * 2021-02-19 2023-12-27 Inhibrx, Inc. Formulations of dr5 binding polypeptides
IL316085A (en) * 2022-04-08 2024-12-01 Inhibrx Biosciences Inc Dr5 agonist and plk1 inhibitor or cdk inhibitor combination therapy
US20250302948A1 (en) * 2022-05-23 2025-10-02 Inhibrx Biosciences, Inc. DR5 Agonist and IAP Antagonist Combination Therapy
CN117285644A (zh) * 2022-06-16 2023-12-26 清华大学 一种相变调节元件及其用途
KR20250131767A (ko) 2022-09-28 2025-09-03 발린크 테라퓨틱스 리미티드 다가 단백질 및 스크리닝 방법
AU2024308381A1 (en) * 2023-06-29 2025-11-20 Odyssey Therapeutics, Inc. Anti-trailr2 antigen-binding proteins and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL100460A (en) * 1990-12-20 1997-06-10 Ixsys Method for optimization of binding proteins and nucleic acids encoding a binding protein produced thereby
US20020147140A1 (en) * 2000-01-31 2002-10-10 Rosen Craig A. Nucleic acids, proteins, and antibodies
KR20070010046A (ko) 2004-04-06 2007-01-19 제넨테크, 인크. Ｄｒ5 항체 및 그의 용도
MX2007008017A (es) 2004-12-31 2007-09-12 Genentech Inc Polipeptidos que se ligan a br3 y usos de los mismos.
AU2006216683A1 (en) 2005-02-24 2006-08-31 Cemines, Inc. Compositions and methods for classifying biological samples
EP1937720B1 (en) 2005-08-18 2014-04-09 Ramot at Tel-Aviv University Ltd. Single chain antibodies against beta-amyloid peptide
CA2632417A1 (en) 2005-12-06 2007-06-14 Domantis Limited Ligands that have binding specificity for egfr and/or vegf and methods of use therefor
AU2007218045B2 (en) 2006-02-20 2011-11-10 Phylogica Limited Method of constructing and screening libraries of peptide structures
JP2008133206A (ja) 2006-11-28 2008-06-12 Yokohama City Univ 緑膿菌に対して感染防御能を誘導できる医薬組成物
EA201000903A1 (ru) 2007-11-30 2011-02-28 Калобиос Фармасьютикалс, Инк. Антитела к pcrv-антигену pseudomonas aeruginosa
SI2285408T1 (sl) * 2008-06-05 2019-02-28 Ablynx N.V. Aminokislinska zaporedja usmerjena proti proteinom ovojnicam virusa in polipeptidi, ki zaporedja vsebujejo za zdravljenje virusnih bolezni
EP2328929A2 (en) * 2008-09-10 2011-06-08 Bac Ip B.V. Antigen-binding proteins that inhibit superantigens for the treatment of skin diseases
EP2408475B1 (en) 2009-03-18 2017-11-15 Wake Forest University Health Sciences Flagellin fusion proteins and use thereof to induce immune responses against pseudomonas aeruginosa
WO2010115141A2 (en) 2009-04-02 2010-10-07 New York University System and uses for generating databases of protein secondary structures involved in inter-chain protein interactions
CN101717775B (zh) * 2009-11-13 2012-01-04 厦门大学 抗人死亡受体5的单链抗体基因
US8962807B2 (en) 2009-12-14 2015-02-24 Ablynx N.V. Single variable domain antibodies against OX40L, constructs and therapeutic use
US9120855B2 (en) * 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
EP2563816B1 (en) 2010-04-27 2014-11-12 National Research Council of Canada Anti-icam-1 single domain antibody and uses thereof
ES2617446T3 (es) * 2010-09-27 2017-06-19 Morphosys Ag Anticuerpo anti-cd38 y lenalidomida o bortezomib para el tratamiento del mieloma múltiple y nhl
CA2815888C (en) 2010-10-25 2020-06-30 National Research Council Of Canada Clostridium difficile-specific antibodies and uses thereof
CN103270047A (zh) 2010-12-23 2013-08-28 因特塞尔奥地利股份公司 Oprf/i剂及其在住院患者和其他患者中的用途
UA118833C2 (uk) * 2011-08-17 2019-03-25 Ґлаксо Ґруп Лімітед Одиничний варіабельний домен імуноглобуліну, який зв'язується з tnfr1
SMT202000091T1 (it) * 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
CA2854806A1 (en) 2011-11-07 2013-05-16 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
US9879093B2 (en) 2011-12-20 2018-01-30 Adaerata, Limited Partnershp Single domain antibodies as inhibitors of PCSK9
WO2013128031A1 (en) 2012-03-02 2013-09-06 Ablynx Nv Pseudomonas aeruginosa pcrv binding single variable domain antibodies
US20130302250A1 (en) 2012-05-07 2013-11-14 The University Court Of The University Of Aberdeen Single domain binding molecule
EP2684896A1 (en) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
US20140161796A1 (en) 2012-09-13 2014-06-12 Andreas Loew Single chain proteins with c-terminal modifications
BR112015010240A2 (pt) 2012-11-06 2017-08-22 Medimmune Ltd Terapias de combinação através do uso de mo-léculas de ligação de psl e de pcrv anti-pseudomonas
CN102924600B (zh) * 2012-11-14 2013-10-30 河南大学 死亡受体5激动性多价抗体及其在制备抗肿瘤药物中的应用
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
US9862777B2 (en) 2013-05-28 2018-01-09 Vib Vzw Single domain antibodies against SOD1 and their use in medicine
KR20160103007A (ko) * 2014-01-10 2016-08-31 각코호진 데이쿄 헤이세이 다이가쿠 재조합 편성 혐기성 그램 양성균

Also Published As

Publication number Publication date
JP2023022214A (ja) 2023-02-14
US20240376220A1 (en) 2024-11-14
AU2016291701B2 (en) 2022-09-29
AU2016291701A1 (en) 2018-01-25
PT3322734T (pt) 2020-11-30
EP3322734A2 (en) 2018-05-23
ES2833773T3 (es) 2021-06-15
IL307994A (en) 2023-12-01
JP2025084923A (ja) 2025-06-03
MX2018000523A (es) 2018-04-13
US11976126B2 (en) 2024-05-07
CN114106178A (zh) 2022-03-01
KR20250017305A (ko) 2025-02-04
MX2023002379A (es) 2023-03-21
CN107922491B (zh) 2021-09-28
KR102760380B1 (ko) 2025-01-31
HK1254433A1 (en) 2019-07-19
RU2018102803A3 (OSRAM) 2019-12-27
JP6807606B2 (ja) 2021-01-06
DK3322734T3 (da) 2020-10-26
US20220064318A1 (en) 2022-03-03
IL256772A (en) 2018-03-29
NZ777930A (en) 2025-05-02
PL3322734T3 (pl) 2021-05-04
RU2748620C2 (ru) 2021-05-28
HRP20201785T1 (hr) 2021-01-22
CN107922491A (zh) 2018-04-17
RU2021111382A (ru) 2021-05-21
KR20180030518A (ko) 2018-03-23
LT3322734T (lt) 2021-02-10
US11117973B2 (en) 2021-09-14
WO2017011837A2 (en) 2017-01-19
US20190309083A1 (en) 2019-10-10
ZA201800238B (en) 2021-07-28
EP3322734A4 (en) 2019-04-17
SMT202100066T1 (it) 2021-03-15
SG10201912410TA (en) 2020-02-27
SI3322734T1 (sl) 2021-02-26
US20170015753A1 (en) 2017-01-19
EP3322734B1 (en) 2020-09-09
HUE051896T2 (hu) 2021-03-29
US10308720B2 (en) 2019-06-04
JP2018522888A (ja) 2018-08-16
BR112018000584A2 (pt) 2018-09-11
IL292037A (en) 2022-06-01
WO2017011837A3 (en) 2017-03-02
JP7244938B2 (ja) 2023-03-23
RU2018102803A (ru) 2019-08-19
RS61062B1 (sr) 2020-12-31
AU2022291498A1 (en) 2023-02-02
EP3798232A1 (en) 2021-03-31
NZ738850A (en) 2024-11-29
CY1123615T1 (el) 2022-03-24
IL256772B (en) 2022-05-01
JP2021046414A (ja) 2021-03-25

Similar Documents

Publication Publication Date Title
US11976126B2 (en) Multivalent and multispecific DR5-binding fusion proteins and methods of modulating immune cells
JP7410143B2 (ja) 二重特異性抗体及びその用途
TWI754800B (zh) 新型抗ox40/pd-l1雙特異性抗體分子、新型抗vegf/gitr雙特異性抗體分子及其用途
CN112969714B (zh) 抗cd40抗体、其抗原结合片段及其医药用途
US11525005B2 (en) Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
TW202436358A (zh) Ｆａｐ／４－１ｂｂ／ｃｄ４０結合分子及其醫藥用途
HK40048814A (en) Multivalent and multispecific dr5-binding fusion proteins
RU2779128C2 (ru) Антитело к cd40, его антигенсвязывающий фрагмент и его медицинское применение
WO2025185656A1 (zh) 抗pd-l1和cd40双特异性抗体及其用途
HK1254433B (en) Multivalent and multispecific dr5-binding fusion proteins
BR112018000584B1 (pt) Polipeptídeo isolado que se liga pelo menos ao receptor de morte 5 (dr5) e seus usos
BR122025011160A2 (pt) Proteínas de fusão com ligação de dr5 multivalentes e multiespecíficas

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210709

EEER Examination request

Effective date: 20210709

EEER Examination request

Effective date: 20210709

EEER Examination request

Effective date: 20210709

EEER Examination request

Effective date: 20210709

EEER Examination request

Effective date: 20210709

EEER Examination request

Effective date: 20210709